Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients-Reference-Cited by-同舟云学术

Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients

Published:2014-05-31 Issue:5 Volume:32 Page:985-994
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Chalret du Rieu Quentin,Fouliard Sylvain,White-Koning Mélanie,Kloos Ioana,Chatelut Etienne,Chenel Marylore

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-014-0118-1.pdf

Reference40 articles.

1. Eisenhauer EA, O’Dwyer PJ, Christian M, Humphrey JS (2000) Phase I clinical trial design in cancer drug development. J Clin Oncol 18:684–692

2. Le Tourneau C, Faivre S, Raymond E, Dieras V (2007) Phase I cancer trials methodology. Bull Cancer 94:943–951

3. Ratain MJ, Mick R, Schilsky RL, Siegler M (1993) Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 85:1637–1643

4. Cannistra SA (2008) Challenges and pitfalls of combining targeted agents in phase I studies. J Clin Oncol 26:3665–3667

5. Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708–720

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Bioequivalence of Abexinostat (CRA‐024781) Tosylate Tablets (20 mg) in Chinese Healthy Subjects Under Fasting Conditions;Clinical Pharmacology in Drug Development;2024-07-18

2. Leveraging modeling and simulation to optimize the therapeutic window for epigenetic modifier drugs;Pharmacology & Therapeutics;2022-07

3. Leveraging Modeling and Simulation to Optimize the Therapeutic Window for Epigenetic Modifier Drugs;SSRN Electronic Journal;2022

4. Systems Modeling to Quantify Safety Risks in Early Drug Development: Using Bifurcation Analysis and Agent-Based Modeling as Examples;The AAPS Journal;2021-05-20

5. Utilization of Physiologically Based Pharmacokinetic Modeling in Clinical Pharmacology and Therapeutics: an Overview;Current Pharmacology Reports;2020-05-12